LIPIN-1-METAB: Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency
Study Details
Study Description
Brief Summary
Lipin-1 deficiencies are responsible for severe rhabdomyolysis and muscle pain in childhood. A specific treatment does not exist. Our research team (Pr de Lonlay, Pr Van-Endert, Marine Madrange and Perrine Renard) identified the mechanism of this disease and propose a treatment to decrease rhabdomyolysis outcome and muscle pain. Further to a CPP approval in 2015, several patients have been treated by Hydroxychloroquine Sulfate off label use on a compassionate basis.
The objective of this retrospective study is to describe the safety and efficacy of Hydroxychloroquine Sulfate given on a compassionate basis to patients suffering from Lipin-1 deficiency within a period between 6 and 36 months.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The Lipin-1 deficiency is an inherited autosomal recessive disease caused by two mutations in the LPIN1 gene. Homozygous or compound heterozygous Lipin-1 deficiency causes recurrent acute episodes of rhabdomyolysis and myoglobinuria in children, associated with permanent muscle pain and weakness. The onset of the disease is usually early (before the age of 6 years old) and the disease is severe. The number of acute episodes' ranges from 1 to 10 per patient, mostly during the first 6 years of life (period where illness episodes are most frequent). Some patients die of myoglobinuric bouts, from cardiac arrhythmia, possibly due to hyperkalemia, with a heart probably more sensitive to hyperkaliemia. Mortality rate is around 10%, and is significantly higher when rhabdomyolysis is complicated by renal failure or by cardiac arrest with arrhythmia due to hyperkalemia. A specific treatment does not exist. Altogether these observations indicate that there is a crucial need to identify a treatment.
Our research team (Pr de Lonlay, Pr Van-Endert, Marine Madrange and Perrine Renard) identified the mechanism of this disease. The consequences on myoblasts of patients are TLR9 sequestration in late endosomes and mitophagy impairment, with consecutively mitochondrial DNA accumulation, TLR9 activation, inflammatory cytokines, calcium release and cell death in the presence of TLR9 ligands and a nutrient-poor environment.
Hydroxychloroquine Sulfate, thanks to an anti-TLR9 activity restores control cell phenotypes. In vivo and in vitro results are spectacular. This treatment seems to be able to both decrease the signaling cascade resulting from the activation of TLR9 and to correct the phenotype of patients suffering from the Lipin-1 deficiency.
Further to a CPP approval, several patients have been treated by Hydroxychloroquine Sulfate off label use on a compassionate basis. The objective of this retrospective study is to describe the safety and efficacy of Hydroxychloroquine Sulfate given on a compassionate basis to patients suffering from Lipin-1 deficiency within a period between 6 and 36 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Lipin-1 deficiency Patients suffering from Lipin-1 deficiency havebenefited from an off-label use treatment by Hydroxychloroquine Sulfate as part of their care for at least 6 months. |
Drug: Hydroxychloroquine Sulfate
The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:
Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.
The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose.
|
Outcome Measures
Primary Outcome Measures
- Creatine kinase dosage in plasma [36 months]
- Inflammatory cytokines in plasma [36 months]
Quantitative flow cytometry based mutliplex assays (flow cytometry-based systems (BD™ Cytometric Bead Array)).
- Quantification of mitochondrial DNA in plasma [36 months]
Quantitative PCR to detect mitochondrial DNA, 12s gene.
Secondary Outcome Measures
- Occurrence of intercurrent event [36 months]
Clinical examination.
- Occurrence of rash [36 months]
Clinical examination.
- Gowers sign appearance [36 months]
Clinical examination.
- Occurrence of shortness of breath [36 months]
Clinical examination.
- Occurrence of muscular fatigability [36 months]
Clinical examination.
- Treatment compliance [36 months]
Patient interrogation.
- Occurrence of adverse effect [36 months]
Patient interrogation.
- Dosing of Hydroxychloroquine Sulfate in plasma [36 months]
Compliance.
- Occurence of retinopathy. [36 months]
Fundus eye and electroretinogram.
- Quotation of the different muscles [36 months]
Muscle testing by a physiotherapist.
- 6-min walking test [36 months]
- Test of the number of steps during a 3-min walk [36 months]
- Assessment of pain: VAS [36 months]
Visual analogue scale (VAS) : scale from 1 to 10; compare from one examination to another for a patient (which is his own control).
- Quality-of-life assessment: Pediatric Quality of Life InventoryTM (PedsQL) questionnaire [36 months]
Pediatric Quality of Life InventoryTM (PedsQL) questionnaire adapted to age: child questionnaire and parent questionnaire. Questionnaire of 23 questions scored on 5 points, from 0 (never) to 4 (almost always). The scores are linearly transformed on a scale between 0 and 100, added together and divided by the number of items completed; high scores are associated with a better quality of life related to health.
- Echocardiography [36 months]
Measurement of the wall of the ventricles, ejection fraction.
- Absence of cardiac arrhythmia [36 months]
Electrocardiography
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 3 months
-
Minors with Lipin-1 deficiency which were diagnosed with familiar context analysis followed by genetic diagnosis (two causal mutations on the LPIN1 gene) and treated by Hydroxychloroquine Sulfate off label use on a compassionate basis in the Metabolic Diseases Center of Necker Hospital
-
Patients treated by Hydroxychloroquine Sulfate for at least 6 months
Exclusion Criteria:
- Opposition of parental authority holders
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital Necker-Enfants Malades | Paris | France | 75015 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
- Principal Investigator: Pascale de Lonlay, Professor, Assistance Publique - Hôpitaux de Paris
- Study Director: Caroline Tuchmann-Durand, Pharm. D, Assistance Publique - Hôpitaux de Paris
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP190368